The Phase 2 NEJM trial (2023) Published in the New England Journal of Medicine under the title "Triple-Hormone-Receptor Agonist Retatrutide for Obesity," this trial (NCT04881760) enrolled 338 adults and ran for 48 weeks
We evaluated multiple combinations to identify those in which minimal optimization was necessary to bring the system toward a steady state
[DOI] [PubMed] [Google Scholar] 60.Torimitsu M., Nagase R., Yanagi M., Homma M., Sasai Y., Ito Y., Hayamizu K., Nonaka S., Hosono T., Kise M., et al
Recent advances in science and technology such as combinatorial and refined chemical synthesis techniques, nanotechnology, bioinformatics, computation tools, and advanced formulation can effectively overcome the challenges to develop the garlic organosulfur-based novel antibiotics